Showing results (211-220 of 969) with videos related to
Sort By:
Pageof 97
American Journal of Hematology|August 25, 2015
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decadeTalha Badar, Hagop M Kantarjian, Graciela M Nogueras-Gonzalez, et al.American Journal of Hematology|September 28, 2016
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemiasBrittany Knick Ragon, Hagop Kantarjian, Elias Jabbour, et al.Blood Cancer Journal|May 6, 2020
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemiaIman Abou Dalle, Ahmad Ghorab, Keyur Patel, et al.Cancer|April 6, 2021
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinibKiyomi Morita, Hagop M Kantarjian, Koji Sasaki, et al.American Journal of Hematology|March 31, 2022
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitorsFadi G Haddad, Koji Sasaki, Ghayas C Issa, et al.Leukemia & Lymphoma|August 7, 2020
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 yearsCatherine Kendall Major, Hagop Kantarjian, Koji Sasaki, et al.American Journal of Hematology|July 24, 2013
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemiaAziz Nazha, Hagop Kantarjian, Farhad Ravandi, et al.Leukemia Research|November 9, 2015
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomesTalha Badar, Keyur P Patel, Philip A Thompson, et al.Acta Haematologica|June 19, 2022
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating MutationsSai Prasad Desikan, Farhad Ravandi, Naveen Pemmaraju, et al.Leukemia|June 21, 2020
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemiaMansour Alfayez, Ghayas C Issa, Keyur P Patel, et al.Pageof 97